Abstract

PurposeTo investigate the capabilities of multiparametric MRI including dynamic contrast enhanced (DCE) perfusion and diffusion-weighted imaging (DWI) to discriminate between benign and malignant ovarian masses. MethodsA total of 43 women with a total of 43 ovarian masses were retrospectively included. They had a mean age of 51.26±18.05 (SD) years (range: 20–88years). Twenty women had benign and 23 had malignant ovarian tumors. All women had multiparametric MRI examinations including DWI (b50-b800) and DCE perfusion imaging at 1–5T. Results of DWI (apparent diffusion coefficient [ADC], b-800) and DCE imaging (volume transfer coefficient [Ktrans], rate constant [Kep], interstitial volume [Ve], initial area under the curve [iAUC]) were compared between benign and malignant ovarian masses. ResultsMean ADC was significantly lowed in malignant tumors (0.92±0.25 [SD]×10−3 mm2/s (range: 0.6–1.6×10−3 mm2/s) than in benign tumors (1.37±0.69 [SD]×10−3 mm2/s; range: 0.4–2.9×10−3 mm2/s) (P=0.011). B-800 was significantly greater in malignant tumors (80.61±24.73 [SD] s/mm2; range: 24–110 s/mm2) than in benign ones (61.15±22.17 [SD] s/mm2; range: 38–155 s/mm2) (P=0.010). Ktrans was lower in benign tumors (0.13±0.06 [SD] min−1; range: 0–0.2min−1) than in malignant ones (0.25±0.16 [SD] min−1; range: 0.1–0.8min−1) (P=0.002). Kep was significantly greater in malignant tumors (0.55±0.19 [SD] min−1; range: 0.1–1.9min−1) than in benign ones (0.44±0.38 [SD] min−1; range: 0.2–1.1min−1) (P=0.003). iAUC was greater in malignant tumors (15.59±7.98 [SD] mM/min; range: 6.6–42.1mM/min) than in benign ones (7.98±5.06 [SD] mM/min; range: 0.2–17.7mM/min) (P=0.001). No differences in Ve were found between benign and malignant masses (P=0.084). The area under the ROC curve was significant for all parameters but Ve. Logistic regression analysis revealed 5.590 and 11.637 times higher malignancy risk for an ADC≤0.93×10−3 mm2/s and an iAUC≥13.88mM/min, respectively. ConclusionMultiparametric MRI has high accuracy in discrimination between benign and malignant ovarian masses. Therefore, adding these methods to the more common MRI protocol can help select the best treatment option in women with ovarian mass.

Full Text
Published version (Free)

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call